in the absence of a submission from the holder of the marketing authorisation:
delafloxacin (Quofenix®) is not recommended for use within NHSScotland.
Indication under review: treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice620KB (PDF)
Medicine details
- Medicine name:
- delafloxacin (Quofenix)
- SMC ID:
- SMC2393
- Indication:
For the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
- Pharmaceutical company
- A Menarini Pharmaceuticals UK Ltd
- BNF chapter
- Infections
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 July 2021